ephedrine
ephedrine: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.
ephedrine evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could ephedrine → NEXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) Reported 2020-04-17 · Current development: unknownSource | Approved |
| NEXUS BIOPHARMA INC (NEXS) Reported 2020-04-17 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study
Primary endpoint: Motility index
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with ephedrine?
ephedrine has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.
How many clinical trials involve ephedrine?
BioSniper tracks 1 clinical trial involving ephedrine.
What is ephedrine's latest FDA decision?
The most recent tracked FDA decision for ephedrine is Approval for 1. INDICATIONS AND USAGE EMERPHED and EMERPHED-PFS is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. EMERPHED and EMERPHED-PFS is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. ( 1 ), dated April 17, 2020.